Form 4: Recursion Pharmaceuticals CEO Executes Pre-Planned Stock Transactions

Recursion Pharmaceuticals CEO, Christopher Gibson, executed pre-planned transactions involving the conversion and sale of Class A and Class B common stock, as detailed in a recent SEC Form 4 filing.

Summary

• Christopher Gibson, CEO of Recursion Pharmaceuticals, engaged in multiple transactions involving the company's stock.
• On December 4th and 5th, 2024, Gibson converted 20,000 shares of Class B common stock into Class A common stock on each day.
• Concurrently, he sold 20,000 shares of Class A common stock on each of those days at prices of $7.16 and $7.12 respectively.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Gibson directly owns 736,633 shares of Class A common stock.
• He also indirectly controls a significant number of shares through various entities, including LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.
• Gibson also holds multiple stock options with varying exercise prices and vesting schedules.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not indicate any significant positive or negative development for the company. It is a routine filing.

Positives

• The transactions were executed under a pre-arranged trading plan, indicating a structured approach to stock management.
• The filing provides transparency into the CEO's stock transactions.

Negatives

• The sale of 40,000 shares by the CEO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The CEO's trading activity, even under a pre-planned strategy, could potentially influence market perception of the stock.
• The complexity of the ownership structure, involving multiple entities, could make it difficult for some investors to fully understand the CEO's total holdings.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Recursion Pharmaceuticals.
• Similar filings are regularly made by executives at companies like BioNTech, Moderna, and Regeneron, reflecting standard compliance with SEC regulations.
• The volume of shares traded by Christopher Gibson is within the typical range for executives at companies of similar size and market capitalization.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, but the pre-planned nature of the trades should mitigate any significant concerns.
• The filing provides transparency to stakeholders regarding the CEO's stock transactions.

Key Dates

Keywords

SEC Form 4, Recursion Pharmaceuticals, Christopher Gibson, stock transactions, Rule 10b5-1, Class A Common Stock, Class B Common Stock, insider trading, stock options